Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma(Western University), Suresh Senan(Amsterdam Neuroscience), Mitchell Liu, Sashendra Senthi(Alfred Health), Glenn Bauman(Thomas Jefferson University Hospital), Neil Kopek(McGill University Health Centre), Stephen Harrow(Beatson West of Scotland Cancer Centre), Stewart Gaede(London Health Sciences Centre), George Rodrigues(London Health Sciences Centre), Liam Mulroy(Nova Scotia Cancer Centre), Alexander V. Louie(London Health Sciences Centre), Roel Schlijper(Positive Living North), Michael Lock(London Health Sciences Centre), Brian Yaremko(London Health Sciences Centre), Belal Ahmad(London Health Sciences Centre), Robert Olson(BC Cancer Agency), Suzanne Currie(Beatson West of Scotland Cancer Centre), Joanna Laba(London Health Sciences Centre), Karen Moore(Children's Hospital of Wisconsin), Andrew Warner(London Health Sciences Centre), Xiaotao Qu(London Health Sciences Centre), Anand Swaminath(Juravinski Cancer Centre), Devin Schellenberg(Surrey Place Centre), Cornelis J.A. Haasbeek(University of Amsterdam)
Cited by 1,233
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
|Journal of Clinical Oncology|2014|1.1k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k